CM Management’s Cartesian Therapeutics RNAC Stock Holding History

CM Management’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$625K	Buy	+60,000	New	+$444K	0.4%	63
2024 Q2	–	Sell	-10,183	Closed	-$199K	–	69
2024 Q1	$199K	Sell	10,183 -13,150	-56%	-$279K	0.17%	68
2023 Q4	$483K	Hold	23,333	–	–	0.39%	57
2023 Q3	$742K	Hold	23,333	–	–	0.79%	42
2023 Q2	$784K	Buy	23,333 +3,333	+17%	+$119K	0.76%	41
2023 Q1	$834K	Hold	20,000	–	–	0.99%	39
2022 Q4	$678K	Hold	20,000	–	–	0.81%	42
2022 Q3	$984K	Hold	20,000	–	–	1.1%	33
2022 Q2	$786K	Buy	20,000 +3,333	+20%	+$98.8K	0.84%	40
2022 Q1	$615K	Buy	16,667 +3,334	+25%	+$209K	0.52%	57
2021 Q4	$1.3M	Hold	13,333	–	–	0.99%	32
2021 Q3	$1.66M	Hold	13,333	–	–	1.24%	28
2021 Q2	$1.67M	Hold	13,333	–	–	1.21%	29
2021 Q1	$1.81M	Buy	13,333 +2,500	+23%	+$310K	1.35%	20
2020 Q4	$985K	Buy	+10,833	New	+$939K	0.91%	37

Other funds holding RNAC

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CM Management's RNAC Position: Q2 2026 in Review

CM Management opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 60,000 shares worth $625K. The stake represents 0.4% of the portfolio and ranks #63 among its holdings. This is a return to the name: CM Management previously reported a position in RNAC as recently as Q1 2024.

CM Management first reported a position in RNAC in Q4 2020 and has held it in 15 quarters since. The position peaked at $1.81M in Q1 2021. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

CM Management held 60,000 shares of Cartesian Therapeutics worth $625K as of Q2 2026.
Cartesian Therapeutics was a new CM Management position in Q2 2026.
Cartesian Therapeutics made up 0.4% of CM Management's portfolio in Q2 2026, its #63 holding.
CM Management first reported a position in Cartesian Therapeutics in Q4 2020 and has held it in 15 quarters since.
CM Management's Cartesian Therapeutics position peaked at $1.81M in Q1 2021.
95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on CM Management's 13F filing for Q2 2026, filed 13 Aug 2026.